Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
EPS Numerator––Basic
Income from continuing operations	[1]	$ 1,320	$ 2,130	$ 6,380	$ 7,141
Less: Net income attributable to noncontrolling interests		0	9	25	23
Income from continuing operations attributable to Pfizer Inc.		1,320	2,122	6,355	7,118
Less: Preferred stock dividends––net of tax		0	0	1	1
Income from continuing operations attributable to Pfizer Inc. common shareholders		1,320	2,121	6,354	7,117
Discontinued operations––net of tax	[1]	0	8	0	14
Less: Discontinued operations––net of tax, attributable to noncontrolling interests		0	0	0	0
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders		0	8	0	14
Net income attributable to Pfizer Inc. common shareholders		1,319	2,130	6,355	7,131
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		1,320	2,121	6,355	7,117
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 1,320	$ 2,130	$ 6,355	$ 7,131
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[1]	6,066	6,168	6,095	6,176
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase (shares)		72	75	68	83
Weighted-average number of common shares outstanding––Diluted	[1]	6,138	6,243	6,164	6,259
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)	[2]	36	55	56	48

[1] Amounts may not add due to rounding.

[2] These common stock equivalents were outstanding for the nine months ended October 2, 2016 and September 27, 2015, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.